News Health

Friday 19 September 2014

Study finds common Arthritis drug may slow Alzheimer's

Scott D'Arcy

Published 17/07/2014 | 02:30

  • Share
The anti-inflammatory drug Entanercept, could potentially slow the progress of Alzheimer's disease according to a study conducted at the University of Southampton. Picture credit: Getty Images/iStockphoto
The anti-inflammatory drug Entanercept, could potentially slow the progress of Alzheimer's disease according to a study conducted at the University of Southampton. Picture credit: Getty Images/iStockphoto

A drug commonly used to treat arthritis could potentially slow the progress of Alzheimer's disease, a study has found.

  • Share
  • Go To

Scientists at the University of Southampton conducted a small control study with a group of 41 patients exhibiting mild or moderate Alzheimer's, giving them either the anti-inflammatory drug Etanercept or a placebo every week over a period of six months.

Each patient was then assessed for memory, efficiency of day-to-day activities and behaviour and the symptoms of those who had taken the Etanercept did not get any worse, while those on the placebo showed decline.

Professor Clive Holmes, who led the study and presented the results at the Alzheimer's Association International Conference in Denmark yesterday said the results were better than his team expected but would need to be tested on a larger scale.

He said: "We have shown that using Etanercept in patients who have Alzheimer's disease would be safe and has positive outcomes after six months. However this is a small study and should now be tested in a larger clinical trial."

The drug, trade name Enbrel, blocks a protein in the body called tumour necrosis factor (TNF) which forms part of the body's defences against diseases and injuries. But Professor Holmes' team have shown Alzheimer's patients with high levels of TNF do worse than those with low levels.

Professor Holmes said: "A large number of anti-inflammatory approaches have been tried in patients with established Alzheimer's, but with little evidence of efficacy.

"There are very few studies that have come out with everything moving in the right direction. We have shown that a targeted approach against TNF offers protection against the development of the disease.

"Our study was small and lasted for six months so it needs to be developed further, however our projections suggest that the benefits would continue. This now needs to be tested," he said.

Press Association

Read More

Editor's Choice

Also in Irish News